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Abstract 
Background: Electronic cigarettes (e-cigarettes) have experienced a tremendous increase in use. 
Unlike cigarette smoking, the effects of e-cigarettes and their constituents on mediating vascular 
health remain understudied. However, given their increasing popularity, it is imperative to 
evaluate the health risks of e-cigarettes, including the effects of their ingredients, especially 
nicotine and flavorings. 
Objectives: To investigate the effects of flavored e-cigarette liquids (e-liquids) and serum 
isolated from e-cigarette users on endothelial health and endothelial cell dependent macrophage 
activation. 
Methods: We used human induced pluripotent stem cell-derived endothelial cells (iPSC-ECs) 
and a high-throughput screening approach to assess endothelial integrity following exposure to 6 
different e-liquids with varying nicotine concentrations and to serum from e-cigarette users. 
Results: The cytotoxicity of the e-liquids varied considerably, with the cinnamon-flavored 
product being most potent and leading to significantly decreased cell viability, increased reactive 
oxygen species (ROS) levels, caspase 3/7 activity, and low-density lipoprotein uptake, activation 
of oxidative stress-related pathway, and impaired tube formation and migration, confirming 
endothelial dysfunction. Upon exposure of ECs to e-liquid, conditioned media induced 
macrophage polarization into a pro-inflammatory state, eliciting the production of interleukin-1β 
(IL-1β) and IL-6, leading to increased ROS. After exposure of iPSC-ECs to serum of e-cigarette 
users, we observed increased ROS linked to endothelial dysfunction, as indicated by impaired 
pro-angiogenic properties. We also noted an increase in inflammatory cytokine expression in 
serum of e-cigarette users. 
Conclusions: Acute exposure to flavored e-liquids or e-cigarette use exacerbates endothelial 
dysfunction, which often precedes cardiovascular diseases. 
 
Key Words: E-cigarette aerosol, iPSC-ECs, e-liquid flavoring, endothelial dysfunction 
 
Abbreviations 
CRP = c-reactive protein 
CVD = cardiovascular disease 
E-cigarette = electronic cigarette 
E-liquids = electronic cigarette liquids 
iPSC-ECs = induced pluripotent stem cell-derived endothelial cells 
PG = propylene glycol 
PLT = platelet 
ROS = reactive oxygen species 
VG = vegetable glycerin 
 
Condensed Abstract 
E-cigarettes have seen a rapid increase in use although their effects on vascular health remain 
understudied. Here, we investigated the effects of flavored e-cigarette liquids (e-liquids) on 
endothelial health by exposing human induced pluripotent stem cell-derived endothelial cells 
(iPSC-ECs) to different e-liquids with varying nicotine concentrations. While cytotoxicity varied 
among the tested flavors, the cinnamon-flavored product was most potent leading to decreased 
cell viability, increased oxidative stress and caspase activity, and impaired tube formation 
confirming endothelial dysfunction; results which were further corroborated using e-cigarette 
3 
users' serum. Our results using iPSC-ECs implicate acute exposure to flavored e-liquids with 
endothelial dysfunction.  
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Introduction 
Cigarette smoking causes one out of every three deaths that result from cardiovascular 
disease (CVD), leading to more than 480,000 premature deaths each year in the United States 
alone (1). While the detrimental effects of conventional cigarette smoking in CVD are well 
documented and smoking prevalence is declining, an explosive increase in the use of electronic 
cigarettes (e-cigarettes), especially among youth, is happening with scarce scientific evidence on 
their toxicity and health effects (2,3). 
E-cigarettes are devices designed to deliver an aerosol containing nicotine by heating a 
liquid solution (often called e-liquid or e-juice) that typically uses propylene glycol (PG) and/or 
glycerol (glycerin) as a vehicle for nicotine and flavoring agents. Although e-cigarettes are 
relatively new to the market, they are an increasingly popular alternative to conventional tobacco 
cigarettes and encompass a wide range of product types and brands. As of 2014, there were more 
than 450 e-cigarette products with nearly 8,000 unique flavors available (4). While most of the 
flavoring chemicals in e-liquids may meet the generally recognized as safe (GRAS) standard for 
ingestion as food additives, they have not been adequately tested as inhalants. In fact, some 
popular flavorings are known to be toxic, including diacetyl (buttery flavor), acetyl propionyl 
(caramel or buttery flavor), and benzaldehyde (fruity taste). Recently, the Food and Drug 
Administration released a statement limiting the sales of flavored e-cigarettes except tobacco, 
menthol, and mint flavor in an effort to prevent a new generation of nicotine addicts (5). Despite 
the rapid increase in popularity, the potential for harmful cardiovascular effects following the use 
of inhaled e-cigarette flavoring chemicals has been largely unexplored.   
To date, the toxicological studies conducted on e-cigarettes have been mostly limited to 
cytotoxicity studies using established cell lines. Early on, limited studies of e-cigarette vapor 
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showed that e-cigarettes delivered much lower levels of carcinogens in aerosols when compared 
with conventional cigarette smoke (6,7). At this time, the cardiovascular risk of e-cigarettes is 
not clear; however, some e-liquid flavorings have been shown to be cytotoxic in cellular models 
including pulmonary fibroblasts, human embryonic stem cells, and neural stem cells (6,8).    
 The vascular endothelium plays an important role in vascular function through 
elaboration of paracrine factors that regulate vascular tone, cell adhesion, fibrinolysis, and blood 
flow (9). Smoking causes endothelial dysfunction, which is a risk factor for CVD (10). It has 
been hypothesized that the use of e-cigarettes is associated with endothelial cell damage leading 
to acute endothelial dysfunction (11), but further in-depth studies are warranted. Despite the 
extensive use of induced pluripotent stem cells (iPSCs) in other areas of research, no previous 
studies have leveraged the powerful platform of human iPSC-derived endothelial cells (iPSC-
ECs) to assess the potential health risks of e-cigarettes on endothelial integrity. Here we used 
iPSC-ECs to evaluate the effects of flavored e-liquids on endothelial health and to understand the 
cross-talk between endothelial cells and macrophages. We further validated our results using 
serum collected from e-cigarette users and conventional cigarette smokers to assess the potential 
effects of e-cigarette use on cardiovascular function.   
Methods 
Detailed methods and supporting data are available in the Online Appendix. 
Differentiation of iPSC-ECs 
The iPSCs (over passage 20) from 3 healthy individuals were split at a 1:12 ratio using 
EDTA as described previously (12), and grown for 3-4 days until they reached ~75% confluence. 
For endothelial cell differentiation and characterization protocol, please refer to the Online 
Appendix. 
6 
E-cigarette liquids (e-liquids) 
Six different e-liquids were purchased online: Freedom Smoke USA (Tucson, AZ), 
Johnson Creek (Johnson Creek, WI), and E Liquid Market (Birmingham, AL) in 0, 6, and 18 
mg/ml of nicotine concentrations and stored at 4°C in the dark (Online Table 1). The bottles 
were chosen to represent the three most common vehicle types (50% PG:50% vegetable glycerin 
(VG), 80% PG:20% VG, and 100% VG) and a range of popular flavors. 
Patients’ serum sample collection 
The subject population consisted of 5 healthy non-smokers (non-smoker), 5 active 
cigarette smokers (cigarette), and 2 dual users of e-cigarettes and cigarettes and 2 sole users of e-
cigarettes (e-cigarette).  We included serum from both sole users of electronic cigarettes and dual 
users of electronic cigarettes and combustible cigarettes in our study because both patterns of use 
are common. We combined the two into a single group (e-cigarette) as most recruited 
participants were traditionally long-term cigarette smokers who started the use of e-cigarettes as 
an alternative to quitting the use of cigarettes. This is also due to the recruited population having 
a mean average age of 29, whereas most solely e-cigarette users with no prior smoking history 
tend to be younger. Depending on the population and the wording of the questions, 25-70% of 
electronic cigarette users describe themselves as dual users (13,14).  The participants classified 
as e-cigarette users reported using their e-cigarettes an average of 27.5 ± 5.0 days a month, with 
9.8 ± 3.3 e-cigarette sessions (more than 2 puffs) per day. Dual users smoked less than 2 packs of 
cigarettes a month. Cigarette smokers reported 29.8 ± 0.4 days of smoking in the past 30 days 
and 10.1 ± 3.4 cigarettes per day.  All subjects were healthy individuals free of other major 
cardiovascular risk factors. Demographic and clinical characteristics of subjects are summarized 
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in Online Table 2.  Informed consent was obtained from all subjects and the conduct of the 
study was approved by the University of California, San Francisco Institutional Review Board.  
Participants in the study were asked not to use combustible cigarettes for 7 days before 
all study visits and to abstain from the use of cigarettes, e-cigarettes, food, and caffeinated drinks 
for 12 hours prior to the study day. To ensure abstinence from tobacco products, carbon 
monoxide (CO) and nicotine levels were tested at the start of each visit. For the e-cigarette study, 
the subjects used an e-cigarette containing RY4-flavored e-liquid (Changning Dekang Ltd, 
Shenzhen, China) with 16 mg/ml nicotine and instructed to use it for a total of 10 minutes (1 puff 
every 30 seconds, each puff lasting 2 seconds). For the cigarette condition, subjects smoked a 
Marlboro cigarette for 10 minutes or until the cigarette went out, by taking 2 puffs per minute, 
each puff lasting 2 seconds.  
Statistical analysis 
Statistical analysis and graphs of data were performed with SigmaPlot 13.0 (SPSS Inc). 
An unpaired two-tailed Student’s t-test for normal distributed variables and Mann-Whitney Test 
for non-normal distributed variables were used for two-group comparisons. Differences of more 
than two groups were performed using analysis of variance (ANOVA) with Bonferroni post-hoc 
analysis. When more than two independent variables were present, a two-way ANOVA with 
Bonferroni correction was used. To test for serial changes, a one-way repeated-measures 
ANOVA was used. Normal distribution was tested with the Shapiro-Wilks test. All data were 
summarized as mean ± standard deviation (s.d.) or mean ± standard error mean (s.e.m.) and 
Bonferroni correction was used for multiple comparisons as indicated. P value <0.05 was 
considered statistically significant. 
Results 
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Assessment of cell viability, ROS generation, and apoptosis in iPSC-ECs after exposure to e-
cigarette liquids 
Two iPSC lines per individual from three healthy individuals were differentiated into 
iPSC-ECs using chemically defined conditions (Online Figure 1A). Following CD144 
purification, iPSC-ECs maintained their identity as demonstrated by a higher expression of 
endothelial-specific marker genes and proteins (Online Figure 1B-1E). Immunostaining showed 
an increase in the expression of intracellular adhesion molecule-1 (ICAM-1) upon cytokine 
tumor necrosis factor (TNF)-α stimulation. Lipid uptake was also confirmed using fluorescent 
acetylated-low density lipoprotein (Ac-LDL), demonstrating the in vitro functionality of these 
iPSC-ECs.  
To examine the effects of e-liquids on cell viability, iPSC-ECs were treated with serial 
dilutions of 6 commercially available e-liquids at varying nicotine concentrations (0, 6, and 18 
mg/ml) for 48 hours (Online Table 1). We observed that flavored e-liquids had varying effects 
on cell survival. While the fruit-flavored Rainier (Figure 1A), sweet tobacco with undertones of 
caramel and vanilla-flavored RY4 (Figure 1B), tobacco-flavored Red Oak Tennessee Cured 
(Figure 1C), and sweet-flavored Butter Scotch (Figure 1D) had moderate cytotoxic effects on 
iPSC-ECs, treatment with cinnamon-flavored Marcado led to a strong cytotoxic effect (Figure 
1E). In addition, the menthol tobacco-flavored Tundra (Figure 1F) also had strong cytotoxic 
effects on iPSC-ECs at 1% dose of concentration with or without nicotine. 
Oxidative stress has been widely implicated as a major factor in endothelial injury (15). 
To determine whether e-liquids regulate reactive oxygen species (ROS) production, H2O2 levels 
in iPSC-ECs were determined after exposure to increasing doses of flavored liquids. As shown in 
Figure 2, most e-liquid exposure for 48 hours, regardless of the flavor, led to increased H2O2 in a 
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dose-dependent manner. This increase in ROS was especially marked when iPSC-ECs were 
exposed to the cinnamon-flavored Marcado e-liquid at 0.3% and 1% dose (Figure 2E) or the 
menthol tobacco-flavored Tundra e-liquid at 1% dose (Figure 2F). 
To elucidate the mechanisms underlying the reduction in iPSC-EC viability by e-liquid 
exposure, we then examined the activities of caspase-3 and caspase-7 in iPSC-ECs following e-
liquids treatments. Both caspases were significantly more active in iPSC-ECs treated with most 
e-liquids compared to control, and the maximum response was observed when cells were treated 
with either Marcado- or Tundra-flavored e-liquids (Figure 3).  In all measured parameters, 
including cytotoxicity, ROS generation, and apoptotic activities, we observed an increasing trend 
as the nicotine concentration increased, though the overall difference was not significant. Finally, 
two solvents that were used in all six flavored e-liquids, vegetable glycerin (VG) and propylene 
glycol (PG), did not affect cell viability, ROS level, or caspase activities (Online Figure 2). 
Assessment of endothelial functions in iPSC-ECs after addition of e-cigarette liquids 
We investigated the influence of e-liquids on tube formation of iPSC-ECs, which reflects 
properties relevant to angiogenesis. Tubes were evaluated 16 hours after seeding in growth 
medium supplemented with three e-liquids: Marcado, RY4, and Tundra.  Addition of the two 
most toxic e-liquids, cinnamon-flavored Marcado (Figure 4A and 4B) and menthol tobacco-
flavored Tundra (Online Figure 3A and 3B), led to a significant decrease in the number of 
meshes and nodes, percent of mesh area, and the total tube length in iPSC-ECs, compared with 
controls. Similar findings were also observed in iPSC-ECs supplemented with the less toxic RY4 
(Figure 4C and 4D). 
Next, we investigated the effect of Marcado or RY4 e-liquid on more specific endothelial 
functions, such as LDL and lipid uptake and cell migration. Our results indicate that incubation 
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with e-liquid of both flavors led to increased uptake of both LDL (Figure 4E) and free fatty 
acids in iPSC-ECs (Online Figure 3C), an important link in the onset of inflammation and 
impaired endothelial function (16,17). The increase in LDL uptake was dependent on nicotine 
concentration within e-liquid. In addition, as shown in Figure 4F and 4G, exposure to each e-
liquid caused significant reduction in iPSC-EC migration, as determined by the rate of wound 
closure and scratch width recovery. Similarly, using HUVECs as a positive control, we found 
free fatty acids to be significantly increased (Online Figure 3D), and migration rate to be 
severely compromised in the presence of e-liquids (Online Figure 3E and 3F). The results on 
cell migration were mostly independent of nicotine concentration, suggesting that the observed 
impairment of endothelial cell functions is associated with the combination of flavor additives 
and nicotine.  
Cross-talk between e-liquid treated endothelial cells and macrophages 
To understand the impact of e-liquid on the cross-talk between ECs and macrophages, we 
analyzed macrophages exposed to conditioned media from iPSC-ECs treated with e-liquid. 
Conditioned media from iPSC-ECs without e-liquid treatment was included as a control 
condition. As shown in Figure 5A, e-liquids, such as Marcado and RY4, triggered macrophage 
dual polarization compared with control groups.  Especially for Marcado flavor, we found that 
the percentage of macrophages expressing CD40 (M1 marker) and CD163 (M2 marker) was 
increased with iPSC-EC-conditioned media treated with 18 mg/ml of nicotine compared to 0 
mg/ml of nicotine (13.0±0.1% vs 2.3±0.2% and 24.4±1.8% vs 18.9±1.6%, respectively). 
We also examined the effects of conditioned media collected from iPSC-ECs treated with 
e-liquid on pro-and anti-inflammatory cytokine production in macrophages. We found that 
exposure to conditioned media from iPSC-ECs treated with e-liquid Marcado significantly 
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increased inflammatory factors produced by M1 macrophages, such as IL-1β and IL-6, and M2-
related cytokine IL-10 (Figure 5B), whereas no significant changes in cytokine expression were 
found in those with e-liquid RY4 (data are not shown). We also found that intracellular ROS 
levels in the macrophages were significantly increased following treatment with conditioned 
media from iPSC-ECs treated with Marcado containing 18 mg/ml of nicotine (Figure 5C). 
Effects of acute cigarette use and smoking on serum nicotine levels and circulating leukocyte 
populations 
We then sought to gain a better understanding of the effects of e-cigarette use in vivo by 
recruiting nonsmokers, cigarette smokers, and e-cigarette users (sole or dual users of cigarettes). 
As nicotine is the key active ingredient in both e-cigarettes and conventional cigarettes, serial 
changes in the levels of nicotine and its major proximate metabolite, cotinine, were assessed in 
participants’ blood prior to (-1 hour), immediately after (0 hour), 1 hour, and 3 hours post-usage. 
Serum nicotine concentrations before tobacco product use (-1 hour) were below 1.5 ng/ml in 
both groups, demonstrating compliance with the overnight hold on tobacco products (Table 1). 
In both groups, there was a significant increase in serum nicotine concentrations immediately 
after product use. The uptake of nicotine from an e-cigarette was similar to a conventional 
cigarette, with maximal mean serum nicotine concentrations reaching 12.3 ng/ml and 12.6 ng/ml, 
respectively. Furthermore, results of total white blood cells (WBCs) and their subpopulations 
revealed no significant differences among nonsmokers, e-cigarette users, and smokers (Table 2). 
Similarly, there were no significant differences between e-cigarette and cigarette smoker groups 
pre- and post-smoking in terms of the mean platelet (PLT) count, although PLT at -1 hour was 
significantly lower (after adjustment for multiple comparisons) in both cigarette smoker and e-
cigarette user groups in relation to nonsmokers.  
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Acute effects of tobacco product use on intracellular ROS and tube formation of iPSC-ECs and 
inflammatory cytokines in serum 
To explore how the use of tobacco products affects ROS production and angiogenic 
signaling in vivo, we next incubated iPSC-ECs with serum derived from nonsmokers, e-cigarette 
users, and cigarette smokers, as described above.  In the -1 hour samples collected after an 
overnight hold on food, alcohol, and tobacco, we observed significantly higher intracellular ROS 
in the cells incubated with serum from e-cigarette users and smokers as compared with serum 
from nonsmokers (Figure 6A), further heightened by the serum collected immediately after (0 
hour), 1 hour, and 3 hours post-usage of a single e-cigarette or cigarette (Figure 6B). Treatment 
of iPSC-ECs with serum collected before and 3 hours after smoking also revealed impairment of 
the tube-formation capability compared to controls treated with serum from nonsmokers (Figure 
6C). We subsequently measured 62 human inflammatory cytokines in the serum from e-cigarette 
and cigarette users pre- and post-smoking (Online Table 3).  Levels of interleukin-6 (IL-6), 
ICAM-1, macrophage colony-stimulating factor (MCSF), and monocyte chemoattractant protein-
1 (MCP-1) in serum of e-cigarette users and cigarette smokers after smoking were significantly 
higher than prior to smoking (Figure 7) but lost statistical significance after adjustment for 
multiple comparisons. In addition, a trend towards increased levels of all other cytokines was 
observed in the serum of both e-cigarette users and cigarette smokers after smoking compared 
with the levels before smoking, and no cytokine level showed a significant difference between e-
cigarette users and cigarette users. 
Gene and functional enrichment analysis with the addition of e-cigarette liquids 
Based on the results from our in vitro experiments, we next investigated the effects of 
two flavored e-liquids on the transcriptomic profile of iPSC-ECs (GEO accession number: 
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GSE125217). We chose an e-liquid with high cytotoxicity, Marcado (MAR, 0.03% 
concentration), and one with low cytotoxicity, RY4 (RY, 0.3% concentration), both with and 
without nicotine. Optimal concentrations for each e-liquid flavor were set at 80% cell viability of 
iPSC-ECs after 24 hours of exposure in vitro. Using principal component analysis (PCA), we 
observed that principal component 1 (PC1) reflected the differences between iPSC-ECs that were 
derived from two different individuals (Online Figure 4A), whereas PC2 identified distinct 
clusters corresponding to MAR-treated samples from RY-treated samples, and PC3 further 
separated RY18-treated samples from either RY0-treated or control (CTR) samples (Online 
Figure 4B). Collectively, these data demonstrate that both MAR0 and MAR18 treatment 
markedly affect the transcriptome of iPSC-ECs, whereas RY treatment has little influence at 
either nicotine concentration. Gene Ontology (GO) analysis using a false positive discovery rate 
(pFDR) cutoff of < 0.05 identified a total of 104 DEGs (including 64 up-regulated DEGs and 40 
down-regulated DEGs) in iPSC-ECs after exposure to either MAR0 or MAR18 compared with 
controls (Online Figure 5A and Online Table 4). GO enrichment analysis found that the most 
preserved expression profiles between MAR-treated samples and controls were related to 
oxidation-reduction process, extracellular matrix organization, and response to toxic substances 
(Online Figure 5B and 5C). Chord diagram for top 5 overrepresented pathways (P-value < 0.05) 
included differential expression of genes involved in response to toxic substances, membrane 
bounded vesicles, growth factor binding, pentose biosynthetic process, and oxidation reduction 
process (Online Figure 5D). Interestingly, when we compared differential gene expression in 
iPSC-ECs exposed to MAR0 or MAR18, no significant enriched annotation cluster was detected 
(data not shown). 
Discussion 
14 
Understanding the health effects of e-liquids, especially flavorings, is important for 
establishing short- and long-term safety of e-cigarettes. In this study, we compared the biological 
effects of flavored e-liquids (both with and without nicotine) on iPSC-ECs and found that some 
flavorings had toxic effects on endothelial cell viability and function. The cinnamon-flavored 
product (Marcado) was the most toxic sample tested, producing strong cytotoxicity in iPSC-ECs 
that led to decreased cell survival, impaired angiogenic responses, and increased ROS levels and 
caspase 3/7 activity. Our findings are concordant with the results of recent studies showing that 
cinnamon-flavored e-liquids and aerosols are highly volatile, cytotoxic, and genotoxic to human 
embryonic cells and adult lung cells (8,18). Notably, our results showed that the effects of e-
liquid flavorings on endothelial phenotypes and function including cytotoxicity, ROS level, 
caspase 3/7 activity, pro-angiogenic properties, and migration, were stronger than those of 
nicotine concentration. Similar biological effects of e-liquid flavoring on iPSC-ECs were also 
observed in a gene set enrichment and GO enrichment analyses. We identified changes in the 
expression of genes involved in multiple biological functions, including response to toxic 
substances, membrane-bounded vesicle, growth factor binding, pentose biosynthetic process, and 
oxidation reduction process 24 hours post-exposure to e-liquid flavor, Marcado, with or without 
nicotine. Some of these enriched functional categories from our study were also highlighted in 
previously reported studies performed on a primary 3D airway cell system and mouse lungs 
exposed to e-cigarette aerosol or cigarette smoking, respectively (19,20). 
Nicotine, one of the major active constituents in most smoking products, is primarily 
metabolized by the liver into cotinine (21). Although it has been reported that nicotine absorption 
rate and plasma nicotine levels are lower from e-cigarette use compared to conventional cigarette 
smoking, it could still reach a delayed but comparable level compared to a tobacco cigarette (21). 
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As intensive puffing (i.e., more puffs and greater puff volume) may influence nicotine delivery, 
we applied a similar study design for e-cigarette users and smokers (one 2 second puff every 30 
seconds for 10 minutes). We found that the effect of e-cigarette use on mean plasma nicotine 
levels was similar to tobacco cigarette smoking. Peak plasma nicotine concentration for both 
conventional cigarette and e-cigarette users was observed immediately after smoking, which is 
consistent with previous reports (21,22), indicating that e-cigarettes provide nicotine via rapid 
pulmonary absorption. 
Although studies with conventional cigarettes have shown that acute and long-term 
exposure to smoking increases the risk of CVD via enhanced oxidative stress (9,23), 
inflammation (9), endothelial dysfunction (9,10), and elevated blood pressure (24), studies on the 
effects of e-cigarette nicotine and liquid flavors have been somewhat limited. In the present 
study, we observed that pro-inflammatory markers such as IL-6, ICAM-1, MCSF, and MCP-1 
were elevated in the serum of users of e-cigarettes and conventional cigarettes 3 hours after use 
compared with serum collected prior to smoke, highlighting the danger of even short-term 
exposure to e-cigarette aerosol in vivo. These inflammatory markers are known to play a critical 
role in the pathogenesis of vascular disease. 
We also demonstrated that e-cigarette and cigarette users’ serum expressed elevated basal 
ROS when compared to nonsmokers, which may be linked to activated inflammatory mediators. 
The already elevated basal ROS levels in e-cigarette users’ serum increased rapidly after 
smoking. Accumulating evidence suggests that ROS plays an important role in physiological and 
pathological angiogenesis (9,25). In this study, we found that conditioned media from iPSC-ECs 
with exposure to e-liquid treatment promoted polarization of both M1 and M2 macrophages, 
with a higher tendency of M1 polarization. These M1 polarized macrophages may be, in part, 
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responsible for strong pro-inflammatory profiles, which are linked to increased ROS generation. 
This is consistent with previous studies demonstrating that macrophages produce high levels of 
ROS, which also acts in a feedback-loop regulating macrophage phenotype (25,26). However, 
the exact role of ROS in macrophages activation still requires further investigation. Importantly, 
our data further validated that the presence of ROS in e-cigarette users’ serum after vaping 
flavored e-liquids was associated with endothelial cell dysfunction, as shown by altered tube 
formation in iPSC-ECs. Consistent with this finding, Carnevale et al. (23) observed negative 
effects on markers of oxidative stress (i.e., soluble NOX2-derived peptide and 8-iso-
prostaglandin F2α) and flow-mediated dilation after a single use of e-cigarette, raising concerns 
regarding vascular safety of e-cigarettes. The results from these studies lend further support to 
the harmful effects of e-cigarette use and cigarette smoking in increasing oxidative stress and 
endothelial dysfunction. 
Finally, we performed a characterization of leukocyte responses in smokers, as it has 
been reported that acute and chronic cigarette smoking is followed by a transient elevation of 
WBC count, considered to be a well-established cardiovascular risk factor in epidemiological 
studies (27). In our study, there were no statistically significant differences in either total or sub-
population leukocyte counts between nonsmokers and smokers of either e-cigarettes or 
conventional cigarettes, which is consistent with a previous study (28). However, we did find a 
significantly lower PLT count in smokers compared with nonsmokers which could be due to the 
decreased thrombopoietic activity induced by nicotine commonly seen in chronic smokers (29). 
Regardless of the underlying mechanisms, these changes are important indications of how e-
cigarette use could compromise host immunity. 
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Despite its many strengths, our study has several limitations. First, as we were interested 
in assessing the direct effects of these liquids on vascular health, the results from our in vitro 
evaluation of e-liquid flavoring using iPSC-ECs were restricted to e-liquids and not their 
aerosols, as no heating or combustion was involved. We did, however, add serum from e-
cigarette users into culture media of iPSC-ECs to mimic cellular exposure to e-cigarette aerosol 
that occurs in vivo, including exposure to toxicants that have undergone metabolic activation or 
deactivation. The presence or absence of aerosols may explain the difference observed in 
nicotine effects whereby nicotine present in e-liquids seems to only have a slight effect on ROS 
production and no effect on tube formation, whereas serum collected from both e-cigarette and 
cigarette smokers after smoking, which contains increased levels of nicotine, significantly 
increased ROS production and impaired tube formation. These effects may be due to the lack of 
combustion used in the in vitro settings, which could make e-cigarettes potentially more toxic 
compared with serum collected from both e-cigarette and cigarette smokers which involves 
combustion. Another factor that may contribute to the differential responses is the increased 
molecular complexity of serum collected from patients due to systemic effects of other cell types 
beyond endothelial cells that may be affected by e-cigarettes or cigarettes. Further studies 
exploring the chemical toxicants in the e-liquids, e-cigarette aerosol, and serum in relation to the 
endothelial cytotoxicity and function, are needed to better understand the potential risk from 
toxic compounds generated by e-cigarette products. Second, a fixed puffing protocol used in our 
study at an experimental setting may not reflect actual user puff practice. However, this fixed 
protocol was necessary to allow us to directly compare the results between different subjects 
across separate studies in a standardized manner.  It should be noted that our results on 6 selected 
flavors may not be universally applicable to all e-cigarettes, given the wide variety of e-liquids in 
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the market that can vary in composition by brand. Third, the relatively small volume and sample 
size of sera available precluded the possibility of performing additional assays, and additional 
sample collection may be needed to extrapolate the findings of our study to the general 
population of e-cigarette users. 
Conclusions 
Our data demonstrated that selected e-liquid flavorings have detrimental effects on 
endothelial cell viability and function, changes that are accompanied by increased ROS and 
caspase 3/7 activity. We also showed that the use of e-cigarettes alone is capable of increasing 
plasma nicotine concentrations comparable to levels achieved via conventional cigarette, 
indicating that e-cigarettes provide effective and measurable nicotine delivery. In addition, our 
results show increased ROS generation and inflammatory cytokines present in serum was 
observed in concert with acute e-cigarette use-induced endothelial dysfunction, as indicated by 
impaired tube formation of iPSC-ECs. As e-cigarette use becomes more widespread, additional 
studies of their health effects become more urgent as this understanding could inform both public 
health policy and regulation.  Nonetheless, our current findings are an important first step in 
filling this gap by providing mechanistic insights on how e-cigarettes cause endothelial injury 
and dysfunction, which are an important risk factors for the development of CVD.  
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Perspectives 
Clinical competencies: Exposure of endothelial cells to e-cigarette flavorings or serum of e-
cigarette users leads to endothelial dysfunction associated with decreased viability, increased ROS, 
and impaired proangiogenic properties. 
Translational outlook: Additional studies examining the long-term effects of e-cigarettes on 
cardiovascular safety are needed in large prospective clinical studies.    
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Figure Legend  
Central Illustration. Overview of mechanisms by which e-cigarette use might case acute 
endothelial dysfunction. Exposure of endothelial cells to e-cigarette flavorings or serum of e-
cigarette users leads to endothelial dysfunction associated with increased apoptosis, ROS, and 
inflammation. IL-6 = interleukin-6; ICAM-1 = intracellular adhesion molecule-1; MCSF = 
macrophage colony-stimulating factor; MCP-1 = monocyte chemoattractant protein-1. 
Figure 1. Assessment of e-liquid flavor-induced cytotoxicity in iPSC-ECs. Effects of 6 e-
liquid flavors with different nicotine concentrations on iPSC-EC viability after 48-hour treatment 
were determined using a luminescent CellTiter-Glo 2.0 assay. The data were obtained using 
iPSC-ECs from 3 biological donors and the assay was repeated twice. Data are represented as 
mean ± SD. ap < 0.05, compared to controls within 0 mg nicotine/ml group; bp < 0.05, compared 
to controls within 6 mg nicotine/ml group; cp < 0.05, compared to control within 18 mg 
nicotine/ml group. Statistically significant from controls (Bonferroni-adjusted P<0.05). VG: 
vegetable glycerin; PG: propylene glycol.  
Figure 2. Assessment of e-liquid flavor-induced ROS production in iPSC-ECs. Effects of 6 
e-liquid flavors with different nicotine concentrations on intracellular ROS production in iPSC-
ECs after 48-hour treatment were determined using a ROS-GloTM H2O2 assay. The data were 
obtained using iPSC-ECs from 3 biological donors and the assay was repeated twice. Data are 
represented as mean ± SD. *p < 0.05 and **p < 0.001, compared to controls within each group. 
Statistically significant from controls (Bonferroni-adjusted P<0.05). VG: vegetable glycerin; PG: 
propylene glycol. 
Figure 3. Assessment of e-liquid flavor-induced caspase 3/7 activity in iPSC-ECs. Effects of 
6 e-liquid flavors with different nicotine concentration on caspase 3/7 activity for apoptosis in 
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iPSC-ECs after 48-hour treatment were determined using a Caspase-Glo® 3/7. The data were 
obtained using iPSC-ECs from 3 biological donors and the assay was repeated twice. Data are 
represented as mean ± SD. *p < 0.05 and **p < 0.001, compared to controls within each group. 
Statistically significant from controls (Bonferroni-adjusted P<0.05). VG: vegetable glycerin; PG: 
propylene glycol. 
Figure 4.  Effect of e-liquid treatment on endothelial function of iPSC-ECs. (A and C) The 
cells were incubated with each e-liquid flavor for 16 hours to allow the formation of capillary-
like structures on Matrigel and then imaged by phase-contrast microscopy (x20).  (B and D) 
Quantitative data from the tube-formation assay. (E) LDL uptake was measured in iPSC-ECs 
after treatment of the e-liquid for 2 days. (F) Representative images and (G) quantitative data 
from the migration assay at 0, 4, and 10 hours in the presence of the e-liquid flavors Marcado 
and RY4. The migration data were normalized to time point 0. Data are represented as mean ± 
SEM. *p < 0.05 and **p < 0.001, compared to controls; and #p<0.05, compared to groups treated 
with 0 mg nicotine/ml.   
Figure 5. Effect of conditioned media from iPSC-ECs treated with e-liquid on macrophage 
polarization. (A) Conditioned media was collected from iPSC-ECs after 48 hours of incubation 
with each e-liquid flavor, and then exposed to macrophage-like cells for 48 hours. Phenotype of 
macrophages was analyzed by flow cytometry for M1 (CD40) and M2 (CD163) markers. (B) 
After 48 hours incubation with conditioned media, the media was replaced with the fresh 
macrophage culture media for 16 hours to determine cytokine expression and ROS levels. 
Expression of cytokines produced by macrophages was determined by quantitative real-time RT-
PCR. (C) Intracellular ROS levels produced by macrophages was determined using a ROS-
GloTM H2O2 assay. Data are represented as mean ± SEM. Statistically significant from controls 
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(Bonferroni-adjusted P<0.05). MAR0: Marcado e-liquid without nicotine; MAR18: Marcado e-
liquid with 18 mg/ml of nicotine; RY0: RY4 e-liquid without nicotine; RY18: RY4 e-liquid with 
18 mg/ml of nicotine.  
Figure 6. Effects of sera from active e-cigarette users and cigarette smokers on ROS 
generation and tube formation of iPSC-ECs in vitro. iPSC-ECs were incubated with 10% 
serum from nonsmokers (n=5), e-cigarette users (n=4), and cigarette smokers (n=5) for 48 hours. 
(A) Intracellular ROS production in iPSC-ECs treated with sera collected from nonsmokers, e-
cigarette users, or cigarette smokers at baseline. (B) Serial changes of ROS production in iPSC-
ECs treated with serum collected from smokers before (-1 hours; shown in detail in A) and after 
(0, 1, and 3 hours) smoking.  (C) iPSC-ECs (1 x 104) treated with serum samples from 
nonsmokers or smokers were seeded onto μ-Slide Angiogenesis containing Matrigel® Basement 
Membrane Matrix for 16 hours, and the formation of capillary-like structures were then imaged 
by phase-contrast microscopy (x 20) and quantified. Data are represented as mean ± SD. *p < 
0.05 and **p < 0.001, compared to nonsmokers or baseline; and #p < 0.05, compared to pre-
smoking within each group. 
Figure 7. Serum cytokine levels in active e-cigarette users and cigarette smokers obtained 
before and after smoking. Concentration of IL-6, ICAM-1, MCSF, and MCP-1 in serum from 
e-cigarette users (A) or cigarette smokers (B) were compared before (Pre) and 3 hours after 
smoking (Post). Data are represented as mean ± SEM. *p < 0.05, compared to pre-smoking. IL-6 
= interleukin-6; ICAM-1 = intracellular adhesion molecule-1; MCSF = macrophage colony-
stimulating factor; MCP-1 = monocyte chemoattractant protein-1. 
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Table 1.  Plasma nicotine and cotinine levels at baseline (1 hour prior), immediately after (0 hour), 
1 hour, and 3 hours after smoking.  
Data are presented as mean ± SD. *,ϯ Statistically significant from baseline.  
  Baseline 
Immediately 
After 
1 hour 
After 
3 hours 
After P-value* P-valueϯ 
 (ng/ml) Mean ± SEM 
E-cig 
Nicotine 1.0 ± 0.6 12.3 ± 3.3* 4.5 ± 0.8 2.3 ± 0.4 0.001 - 
Cotinine 127.5 ± 16.7 116.8 ± 16.0 91.6 ± 30.4 82.0 ±26.5* 0.01 - 
Cig 
Nicotine 0.6 ± 0.1 12.6± 1.9* 5.8 ± 0.8ϯ 2.8 ± 0.4 <0.001 0.04 
Cotinine 99.4 ± 33.9 94.1 ± 32.5 96.9 ± 29.8 91.0 ± 27.7 - - 
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Table 2. Peripheral blood counts and lymphocyte subpopulation in 5 nonsmokers, 4 e-cigarette 
users, and 5 cigarette smokers before and after exposure to smoke.  
 Nonsmokers E-cig user Cig smokers 
  Before After Before After 
WBC, k/μl 5.5 ± 0.9 5.5 ± 0.6 5.6 ± 0.8 6.0 ± 0.7 6.4 ± 0.5 
Lymphocytes, % 33.7 ± 0.7 35.7 ± 4.7 33.7 ± 3.9 31.0 ± 3.9 26.1 ± 2.5 
Neutrophils, % 54.9 ± 0.5 51.7 ± 4.6 54.5 ± 3.9 59.5 ± 3.2 63.2 ± 2.3 
Monocytes, % 6.2 ± 0.4 6.2 ± 0.6 6.5 ± 0.3 6.6 ± 0.6 6.2 ± 0.7 
Eosinophils, % 3.1 ± 0.5 3.4 ± 0.6 2.7 ± 0.7 3.0 ± 0.7 2.4 ± 0.8 
Basophils, % 0.5 ± 0.1 0.5 ± 0.1 0.5 ± 0.1 0.3 ± 0.1 0.4 ± 0.1 
RBC, mil/μl 4.7 ± 0.5 4.6 ± 0.1 4.6 ± 0.2 4.3 ± 0.1 4.2 ± 0.1 
HGB, g/dl 13.7 ± 1.4 13.8 ± 0.3 14.0 ± 0.3 13.0 ± 0.4 12.8 ± 0.4 
HCT, % 41.2 ± 4.1 41.1 ± 0.8 41.4 ± 1.0 39.5 ± 1.2 38.3 ± 1.1 
MCV, fl 87.2 ± 1.8 89.9 ± 2.3 90.7 ± 2.1 91.9 ± 1.3* 91.4 ± 1.2 
PLT, k/ μl 304.3 ± 4.2 213.3 ± 21.8* 208.5 ± 25.1 206.8 ± 17.0** 201.3 ± 19.1 
Data are presented as mean ± SD. WBC: white blood cells, RBC: red blood cells, HGB: 
hemoglobin, HCT: hematocrit, MCV: mean volume of red blood cells, PLT: platelets.  *, ** 
Statistically significant from nonsmokers (*p<0.05 and **p<0.001). 
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